Synta trumpets interim data for breast cancer hopeful; Emergent buying Cangene for $222M;

@FierceBiotech: In January, Levin dumped Teva's immunotherapy program. Now, checkpoint receptor drugs are all the rage. More | Follow @FierceBiotech

@JohnCFierce: Galderma Labs axing staff in U.S. shakeup after president exits (gee, the rumors were true). News | Follow @JohnCFierce

@DamianFierce: Imagine being the Novartis worker who picked up Retrophin's call. "Hey, so, remember Syntocinon?" | Follow @DamianFierce

@EmilyMFierce: Congressional budget deal would restore NIH sequester cuts. Coverage | Follow @EmilyMFierce

> Synta Pharmaceuticals ($SNTA) is touting early results for the breast cancer-treating ganetespib, its lead candidate, pointing to interim Phase II data in which the treatment posted a 75% response rate among HER2-positive patients. Release

> Rockville, MD's Emergent BioSolutions ($EBS) has signed a deal to buy Cangene for $222 million, acquiring the company's line of biodefense therapeutics and infectious disease treatments. More

Medical Device News

@FierceMedDev: Avinger draws new financing to back testing of light-enhanced PAD catheter. Article | Follow @FierceMedDev

@MarkHFierce: St. Jude Medical won a CE mark for a larger size of its Portico heart valve, adding to a now-crowded competition. More | Follow @MarkHFierce

@MichaelGFierce: AdvaMed, MDMA commend congressional budget deal as vote approaches. Story | Follow @MichaelGFierce

@GalenMoore: Senesco Announces up to $25.2 Million Equity Financing. Release | Follow @GalenMoore

> Boston Scientific's Watchman stroke-fighting device wins overwhelming FDA panel support. Piece

> T2 brings on 2 Hologic vets as work continues on Candida assay ramp-up. News

Pharma News

@FiercePharma: India's Lupin already launched its copies of Eli Lilly's $5B antidepressant, Cymbalta, in U.S. Half-dozen companies got FDA nod. Poor Lilly. | Follow @FiercePharma

@EricPFierce: Merck KGaA's Allergopharma unit building a €40M plant near Hamburg that will make #allergy meds for China. Release | Follow @EricPFierce

@CarlyHFierce: Here come the Cymbalta copies. FDA approves generics from Teva, Sun, Dr. Reddy's, Lupin and others. Release | Follow @CarlyHFierce

> Think fast: A new cognition study could add $350M to Lundbeck's Brintellix sales. News

> D-Day for Eli Lilly: Generic foes arrive for $5B antidepressant Cymbalta. Article

Vaccines News

> GSK shares data from pivotal PhIII trial of quadrivalent flu vaccine. Story

> Novartis awaits pivotal Bexsero decisions in Canada and Europe. Piece

> Genocea begins a PhI trial of its rival to Pfizer's Prevnar. News

> AstraZeneca eyes 2014 EU launch for 4-in-1 flu vaccine after winning approval. More

> Pentagon tasks Pfizer with radically rethinking vaccine development. Article

> Lundbeck teams with Otsuka on Alzheimer's vaccine development. Item

Pharma Manufacturing News

> ScinoPharma's $113 million China API plant ready to go. News

> Merck KGaA targets China with a planned €40M allergy plant. More

> FDA stationing 10 new drug inspectors in China. Story

> GSK's new manufacturing investments in the U.K. now pass $1 billion. Article

> Cardinal, CVS JV creates more upheaval in U.S. drug supply chain. Piece

> FDA warns NJ lotion maker: Your water does not meet specs. Item

Suggested Articles

It’s been a good year for Intellia: One of its founders, Jennifer Doudna, Ph.D., nabbed the Nobel Prize in Chemistry for her CRISPR research.

After stints at Eli Lilly, Boehringer Ingelheim and Bristol Myers Squibb, Sid Kerkar, M.D., is hopping over to a small biotech.

Two long noncoding RNAs called TROLL-2 and TROLL-3 influence protein signaling to drive the progression of breast cancer, a new study revealed.